Pediatr Gastroenterol Hepatol Nutr.  2012 Mar;15(1):13-18.

Biological Therapy for Inflammatory Bowel Disease in Children

• Na SY
• Shim JO

Abstract

The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.

Keyword

Inflammatory bowel disease; Infliximab; Children

MeSH Terms

Antibodies, Monoclonal
Biological Agents
Biological Therapy
Child
Crohn Disease
Humans
Immunoglobulin G
Immunologic Factors
Inflammatory Bowel Diseases
Necrosis
Tumor Necrosis Factor-alpha
Infliximab
Antibodies, Monoclonal
Biological Agents
Immunoglobulin G
Immunologic Factors
Tumor Necrosis Factor-alpha

Reference

1. Seo JK. Pediatric inflammatory bowel disease: Phenotype, genetic and therapeutic differences between early-onset and adult onset IBD. Korean J Pediatr Gastroenterol Nutr. 2011. 14:1–25.

2. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel disease. Gastroenterology. 2009. 136:1182–1197.

3. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn disease. Gut. 1994. 35:360–362.

4. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn disease. Gastroenterology. 1999. 117:527–535.

5. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn disease: the ACCENT I randomised trial. Lancet. 2002. 359:1541–1549.

6. Hyams JS, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohn's disease in children. Gastroenterology. 2007. 132:863–873.

7. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008. 6:1378–1384.

8. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn disease. N Engl J Med. 2010. 362:1383–1395.

9. Van Moerkercke W, Ackaert C, Jürgens M, Kasran A, Compernolle G, Ballet V, et al. Anti-TNFα Induced Severe Arthralgia as a Manifestation of Autoimmunity? Gastroenterology. 2010. 138:1 Suppl. 60S–61S.

10. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011. 60:571–607.

11. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005. 353:2462–2476.

12. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009. 137:1250–1260.

13. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010. 105:1430–1436.

14. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008. 134:929–936.

15. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011. 9:36–41.

16. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009. 7:874–881.

17. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010. 8:655–659.

18. D'Haens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn disease: an open randomised trial. Lancet. 2008. 371:660–667.

19. Romeo E, Viola F, De Angelis G, Vernuccio A, Pannone V, Bizzarri B, et al. Infliximab As a First Choice Therapy in Children with Newly Diagnosed Crohn's Disease (CD) Promotes Long-Term Sustained Remission and Alters the Course of the Disease. Gastroenterology. 2006. 130:2 Suppl. S11.

20. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008. 134:1861–1868.

21. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn disease treated with combination therapy. Am J Gastroenterol. 2010. 105:1142–1149.